Lam Research: Don't Chase The Stock (Rating Downgrade)

Lam Research: Do…

Western Midstream: Still A High Yielder But No Longer A High Grower (Rating Downgrade)

Western Midstrea…

AI Is Not My Biggest Concern With Stifel Financial (Rating Downgrade)

AI Is Not My Big…

Procter & Gamble: Weak Fundamentals Could Result In A Painful Shave For Investors (Rating Downgrade)

Procter & Ga…

Yum! Brands: The 'Taco Bell-ification' Of KFC (Rating Downgrade)

Yum! Brands: The…

Central Garden & Pet Doesn't Look As Appealing Now (Rating Downgrade)

Central Garden &…

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

From Bargain To …

GDX: Opportune Time To Reduce Gold Miners (Rating Downgrade)

GDX: Opportune T…

LPL Financial: Shifting Gear Into Neutral This Time, As Overvaluation Overshadows Growth (Downgrade)

LPL Financial: S…

Engie: 94% Returns Since 2025; Looking At 2026E (Rating Downgrade)

Engie: 94% Retur…

AI And Credo Technology's Copper Cables Are Breaking Up (Rating Downgrade)

AI And Credo Tec…

Ford's Change In EV Strategy Is Cause For Concern (Rating Downgrade)

Ford's Chan…

ING Groep: Executing Well, But No Longer Undervalued (Rating Downgrade)

ING Groep: Execu…

Visa: A Must-Own Long Term, Just Not A Buy Today (Downgrade)

Visa: A Must-Own…

BAB: I See Less Value In Taxable Munis Now (Rating Downgrade)

BAB: I See Less …

AGCO Corporation: Expect This Fruit To Sour (Rating Downgrade)

AGCO Corporation…

Axos Financial: A Respectful Downgrade After An Excellent Run Higher

Axos Financial: …

Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)

Viridian Therape…

Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade)

Novartis: Upside…

Bristol Myers Squibb: The Rerating Was Fast – The Proof Will Be Slow (Rating Downgrade)

Bristol Myers Sq…

ASML Q4 Preview: AI Momentum Beats Rich Valuation (Rating Downgrade)

ASML Q4 Preview:…

Teladoc Health: Why Low Valuation Doesn't Equal A 'Buy' (Rating Downgrade)

Teladoc Health: …